Ert Pompe denied due to quantity / dose limits by AmeriHealth Caritas?

Confirmed enzyme assay + genetic testing. Specialist Rx (geneticist or metabolic).

EPSDT for under-21 overrides state PDL limits. Orphan Drug Act + FDA approval rebut 'experimental' label. Site-of-care: home infusion appropriate for stable patients per manufacturer REMS.

## Why AmeriHealth Caritas May Impose Quantity Limits on ERT for Pompe Disease

AmeriHealth Caritas, as a Medicaid managed-care organization, applies quantity-limit (QL) edits to specialty biologics including enzyme replacement therapy (ERT) for Pompe disease. These limits are typically set by comparing a standard weight-based dosing formula against the patient's weight at the time the prior authorization was approved. A quantity-limit denial most often occurs when the patient's weight has changed, when the prescribed quantity was entered differently than the QL benchmark, or when the plan's dosing reference does not reflect the FDA-approved prescribing label.

## Why This Denial Is Appealable

The FDA-approved prescribing label for ERT in Pompe disease specifies a dosing regimen that is determined by actual body weight. If the prescribed quantity aligns with the label's dosing instructions for this patient's current weight, a quantity-limit denial is factually incorrect and correctable. Appeals on this basis succeed when the prescriber documents the calculation clearly.

## Federal Appeal Framework

• Internal appeal: File within the timeframe on your denial letter (typically 180 days for Medicaid managed care). AmeriHealth Caritas must respond within 30 days for standard appeals; 72 hours for expedited requests. QL denials tied to a progressive disease often qualify for expedited review.
• External review (ACA §2719): After a final internal denial, request independent external review. The IRO will assess whether the quantity limit is consistent with the FDA label and accepted clinical standards.
• State Medicaid fair hearing: As a Medicaid enrollee, you also have the right to a state fair hearing, which runs parallel to or after the plan-level process. Timelines vary by state but are federally required.

The external-review request window is generally four months from the date of final internal denial.

## Documentation to Gather

• Weight-based dosing calculation: A letter from the prescriber showing the patient's current verified body weight and the quantity of ERT calculated from the FDA-approved label's dosing instructions — confirming that the prescribed quantity matches label guidance exactly.
• FDA prescribing label: The current label for the specific ERT product showing the approved dosing regimen, so the reviewer can verify the prescriber's calculation.
• Recent clinical records: Current weight documented in the chart (dated), along with any clinical notes explaining why the current dose is necessary.
• Denial documentation: The specific quantity limit cited in the denial letter, so the prescriber's letter can address it directly.
• Medical necessity letter: A physician statement explaining that reducing the quantity below the prescribed amount would result in under-dosing below the FDA-approved therapeutic range.

## Criteria-Mapping Structure

Request the AmeriHealth Caritas quantity-limit policy for this specific ERT product. Then map each element:

| QL Policy Element | Supporting Documentation | |---|---| | Approved dosing regimen per FDA label | [Label excerpt showing weight-based dosing] | | Patient's current body weight | [Documented weight from recent clinical visit] | | Prescribed quantity calculation | [Prescriber's step-by-step calculation letter] | | Consistency with approved indication | [Diagnosis confirmation + prescriber letter] |

When the math is laid out explicitly and referenced to the FDA label, quantity-limit appeals for weight-based biologics are among the more straightforward to win.